The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with ...

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last ...

Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470. On the plus side, the Mont Blanc trial of the drug showed that it was as ...

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle ...